Search results
Results from the WOW.Com Content Network
In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. [30] In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118.
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
Pages in category "Drugs developed by AbbVie" The following 128 pages are in this category, out of 128 total. ... This page was last edited on 9 January 2025, at 02: ...
The next area of inquiry will be one that's at the core of AbbVie's wheelhouse: Immunology. Lilly plans to do a clinical trial this fall examining whether tirzepatide could be helpful for treating ...
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, in the United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.
For premium support please call: 800-290-4726 more ways to reach us
On 20 June 2014, Shire rejected a takeover attempt by AbbVie. AbbVie offered £46.11 per share (£27.3 billion or $46.5 billion in total). [30] On 8 July, the offer was increased to $51.5 billion. [31] On 18 July, it was announced that AbbVie would acquire Shire for $54.8 billion. [32]